百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准

智通財經

3小時前

智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新藥BL-ARC002注射液的藥物臨床試驗獲得批准。

公告稱，BL-ARC002通過抗體介導的精準靶向遞送技術及放射性核素強大的腫瘤殺傷能力，與傳統放射性核素偶聯藥物相比，具有更強的靶點特異性、更高的腫瘤富集性，並有望展現出更好的抗耐藥性。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2621371933"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621371933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621371933?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-22 15:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621371933","market":"sh","top_or_hot":-1,"title":"百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准","media":"智通財經","content":"<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/688506\">百利天恒</a>(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新藥BL-ARC002注射液的藥物臨床試驗獲得批准。</p><p>公告稱，BL-ARC002通過抗體介導的精準靶向遞送技術及放射性核素強大的腫瘤殺傷能力，與傳統放射性核素偶聯藥物相比，具有更強的靶點特異性、更高的腫瘤富集性，並有望展現出更好的抗耐藥性。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n百利天恒(688506.SH)創新藥BL-ARC002注射液獲臨床試驗批准\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-03-22 15:41</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><p>智通財經APP訊，<a href=\"https://laohu8.com/S/688506\">百利天恒</a>(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新藥BL-ARC002注射液的藥物臨床試驗獲得批准。</p><p>公告稱，BL-ARC002通過抗體介導的精準靶向遞送技術及放射性核素強大的腫瘤殺傷能力，與傳統放射性核素偶聯藥物相比，具有更強的靶點特異性、更高的腫瘤富集性，並有望展現出更好的抗耐藥性。</p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://www.zhitongcaijing.com/content/detail/1417046.html\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1417046.html","article_id":"2621371933","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621371933","pubTimestamp":1774165288,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新藥BL-ARC002注射液的藥物臨床試驗獲得批准。公告稱，BL-ARC002通過抗體介導的精準靶向遞送技術及放射性核素強大的腫瘤殺傷能力，與傳統放射性核素偶聯藥物相比，具有更強的靶點特異性、更高的腫瘤富集性，並有望展現出更好的抗耐藥性。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"91194":"临工重机股份有限公司（临时代码）","159992":"创新药","688506":"百利天恒","BK1161":"生物科技","BK4023":"应用软件","BK1574":"生物医药B类股","06978":"永泰生物-B","BL":"Blackline Inc.","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BK0239":"医药制造","02615":"百利天恒"},"translate_title":"Baili Tianheng (688506.SH) innovative drug BL-ARC002 injection was approved for clinical trials","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91194":1.5,"159992":1.5,"688506":1.5,"02615":1.5,"BL":1.5,"06978":1.5},"content_text":"智通財經APP訊，百利天恒(688506.SH)公告，公司近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨床試驗批准通知書》，公司自主研發的創新藥BL-ARC002注射液的藥物臨床試驗獲得批准。公告稱，BL-ARC002通過抗體介導的精準靶向遞送技術及放射性核素強大的腫瘤殺傷能力，與傳統放射性核素偶聯藥物相比，具有更強的靶點特異性、更高的腫瘤富集性，並有望展現出更好的抗耐藥性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}